BenBedPhar compiles a comprehensive panel of somatic mutations affecting the KEAP1/NRF2 signaling axis, which plays a central role in redox homeostasis, metabolic regulation, and oncogenic adaptation. The accompanying datasets
summarize experimentally validated genetic alterations in the NFE2L2 gene (encoding NRF2) and its negative regulator KEAP1, collected from preclinical and clinical cancer studies. Each record includes information on the mutation
type, genomic location, amino acid substitution, associated tumor type, and relevant bibliographic references.
The deliverable provides a valuable reference for understanding the molecular diversity and pathological relevance of NRF2/KEAP1 alterations, particularly in non-small cell lung carcinoma (NSCLC), where constitutive NRF2 activation contributes to chemoresistance, tumor progression, and metabolic reprogramming. Beyond NSCLC, the dataset includes mutations reported in hepatocellular, head and neck, and ovarian cancers, highlighting the broader oncogenic impact of deregulated NRF2 signaling. By consolidating dispersed mutation data into an accessible format, this panel supports BenBedPhar’s objectives of data harmonization and translational exploitation of NRF2-related molecular information. It serves as a tool for identifying clinically relevant variants, guiding experimental modeling, and facilitating the integration of genomic findings into pharmacological and biomarker development pipelines.
